- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05029076
Human Bioequivalence Test of Liraglutide Injection
30 agosto 2021 aggiornato da: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so as to provide reference for clinical evaluation and clinical medication;To observe the safety of the test preparation liraglutide injection and the reference preparation Victoza ® in healthy subjects.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
28
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Jilin
-
Changchun, Jilin, Cina, 130021
- Affiliated Hospital of Changchun University of Traditional Chinese Medicine
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 60 anni (Adulto)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Sign the informed consent form before the trial, fully understand the trial purpose, process and possible adverse reactions;
- Able to complete the study according to the requirements of protocol;
- Aged between 18 and 60 years old, both men and women;
- Male ≥50kg, female ≥45kg,body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value);
- No mental abnormalities, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system or metabolic abnormalities;
- Normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, and imageological examination have no clinical significance;
- The female blood pregnancy test is not pregnant, and the subjects (including male subjects) have no pregnancy plan and voluntarily take effective contraceptive measures from 2 weeks before administration to at least 3 months after the last use of the study drug. See the appendix for specific contraceptive measures.
Exclusion Criteria:
- Previous disease of the neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemo-lymphatic system, liver and kidney dysfunction, endocrine system, musculoskeletal system, or other disease that the investigator determines may affect drug metabolism or safety;
- Have a history of fainting needles, fainting blood;
- Known allergy to Liraglutide and its metabolites or any of the excipients of the formulation;
- Those who smoked more than 5 cigarettes per day during the 3 months before the trial.
- History of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 360 ml of beer or 45 ml of 40% alcoholic spirits or 150 ml of wine);
- Donated blood or lost a lot of blood (> 450 ml) within 2 months before taking the study drug ;
- Have taken any drug that changes liver enzyme activity 28 days before taking the study drug (such as liver drug enzyme inhibitor chlorpromazine, cimetidine, ciprofloxacin, metronidazole, etc.; liver drug enzyme inducer barbital Drugs, carbamazepine, rifampicin, dexamethasone, etc.);
- Have taken any prescription, over-the-counter, vitamin product or herbal medicine within 1 month prior to the use of the study drug;
- During the trial it is necessary to use tobacco, alcohol, and caffeine-containing drinks, or certain foods that may affect metabolism (such as grapefruit, grapefruit juice, etc.), or major changes in diet or exercise habits before the test, or other effects that affect drug absorption, Factors such as distribution, metabolism, excretion, etc;
- Have taken the study drug or participated in the drug clinical trial within 2 months before taking the study drug;
- Positive for hepatitis (including hepatitis B and C), HIV or syphilis at screening;
- Female subjects are breastfeeding or have a positive serum pregnancy result during the screening period or during the test;
- Those who have been screened positive for drugs or have a history of drug abuse in the past five years or have used drugs in the 3 months before the trial;
- Blood collection is difficult or cannot tolerate venipuncture blood collection;
- Acute illness during the screening phase or before study medication;
- The subject is unable or can not comply with ward management regulations;
- The subject is unable to complete the study due to personal reasons;
- Other cases judged by researchers to be unsuitable for selection.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Liraglutide injection + Victoza
Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
|
Human glucagon-like peptides-1 analogue
Human glucagon-like peptides-1 analogue
|
Sperimentale: Victoza +Liraglutide injection
Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
|
Human glucagon-like peptides-1 analogue
Human glucagon-like peptides-1 analogue
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Maximum (peak) plasma drug concentration(Cmax)
Lasso di tempo: 0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Maximum (peak) plasma drug concentration
|
0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Time to reach maximum (peak) plasma concentration following drug administration (Tmax)
Lasso di tempo: 0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Time to maximum concentration
|
0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)
Lasso di tempo: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
The area under the plasma concentration curve from 0 to infinity
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Terminal disposition rate constant/terminal rate constant (λz)
Lasso di tempo: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent end elimination rate constant
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Elimination half-life (t1/2)
Lasso di tempo: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
The time required for the highest concentration of the drug in plasma to decrease by half
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent total clearance of the drug from plasma after oral administration (CL/F)
Lasso di tempo: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent total body clearance
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent volume of distribution after non-intravenous administration (Vd/F)
Lasso di tempo: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent volume of distribution
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Bioavailability (systemic availability of the administered dose)
Lasso di tempo: 0 hour(pre-dose, within 60mins) to 72 hours after administration on day1 and day 15.
|
Relative bioavailability
|
0 hour(pre-dose, within 60mins) to 72 hours after administration on day1 and day 15.
|
Adverse Event, Serious Adverse Event and Drug Combination
Lasso di tempo: up to day 15
|
Monitor the safety indicators of subjects during the trial
|
up to day 15
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
body temperature
Lasso di tempo: 1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal body temperature
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
pulse
Lasso di tempo: 1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal pulse
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
blood pressure
Lasso di tempo: 1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal blood pressure
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
clinical symptoms
Lasso di tempo: From the screening period to day 18 after the first administration
|
Any discomfort spontaneously reported by the subject
|
From the screening period to day 18 after the first administration
|
The Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (physical examination)
Lasso di tempo: From the screening period to day 18 after the first administration
|
Monitor the safety indicators of subjects during the trial,For example: skin, mucous membrane, head (head, eyes, ears, nose, mouth), neck, chest (chest, breast, lung, heart), abdomen (liver, gallbladder, spleen, kidney, bladder), spine, limbs, nervous system, lymph nodes, etc,and calculate the Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
From the screening period to day 18 after the first administration
|
The Number of participants with abnormal laboratory examinations
Lasso di tempo: From the screening period to day 18 after the first administration
|
laboratory examination, such as liver function, kidney function, coagulation function, blood routine, urine routine
|
From the screening period to day 18 after the first administration
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
21 maggio 2019
Completamento primario (Effettivo)
1 giugno 2019
Completamento dello studio (Effettivo)
1 luglio 2019
Date di iscrizione allo studio
Primo inviato
24 agosto 2021
Primo inviato che soddisfa i criteri di controllo qualità
30 agosto 2021
Primo Inserito (Effettivo)
31 agosto 2021
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
31 agosto 2021
Ultimo aggiornamento inviato che soddisfa i criteri QC
30 agosto 2021
Ultimo verificato
1 agosto 2021
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ZDTQ-BE-2019-LLLT
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Diabete di tipo 2
-
AmgenCompletato
-
Paolo MilaniReclutamentoAmiloidosi | Amiloidosi cardiaca | ATTR Amiloidosi Wild TypeItalia
-
Steen Hvitfeldt PoulsenReclutamentoATTR Amiloidosi Wild TypeDanimarca
-
Oncology Institute of Southern SwitzerlandUniversity of Kiel; Ente Ospedaliero Cantonale, BellinzonaCompletato
-
AmgenCompletatoCancro colorettale metastatico RAS wild-type
-
Henan Cancer HospitalCompletatoCancro colorettale metastatico KRAS, NRAS e BRAF V600E wild-type
-
Austin Neuromuscular CenterAlnylam PharmaceuticalsReclutamentoPolineuropatie | Amiloidosi da transtiretina | Amiloidosi correlata alla transtiretina di tipo selvaggio (ATTR). | Amiloidosi cardiaca da transtiretina wild-type | Amiloidosi ATTR di tipo selvaggioStati Uniti
-
Denver Health and Hospital AuthorityIscrizione su invitoDisturbo evitante restrittivo dell'assunzione di cibo | Anoressia Nervosa, Binge Eating/Purging Type | ARFIDE | Tipo restrittivo di anoressia nervosaStati Uniti
-
Rosemary Claire RodenChildren's Miracle NetworkIscrizione su invitoBulimia nervosa | Comportamento impulsivo | Eliminazione (disturbi alimentari) | Problemi alimentari | Disturbi alimentari in adolescenza | Anoressia Nervosa/Bulimia | Anoressia in adolescenza | Anoressia Nervosa, Atipica | Anoressia Nervosa, Binge Eating/Purging TypeStati Uniti
-
Assistance Publique - Hôpitaux de ParisReclutamentoDiagnosi radiologica iniziale ammissibile per la resezione del tumore | Diagnosi radiologica iniziale compatibile con glioblastoma di nuova diagnosi (IDH wild-type) | Idoneo per lo standard di cura, inclusa la temoradiazione simultanea e la temozolomide adiuvanteBelgio, Francia, Svizzera
Prove cliniche su Liraglutide injection
-
Changhai HospitalNon ancora reclutamentoLinfoma a cellule B recidivato o refrattario
-
Ruijin HospitalReclutamentoLinfoma a cellule B recidivato o refrattarioCina
-
Shanghai Junshi Bioscience Co., Ltd.CompletatoCarcinoma polmonare non a piccole cellule avanzato naïve al trattamentoCina
-
Bio-Thera SolutionsCompletato
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... e altri collaboratoriNon ancora reclutamentoCarcinoma rinofaringeo ricorrenteCina
-
Beijing Biostar Pharmaceuticals Co., Ltd.Reclutamento
-
Hallym University Medical CenterReclutamento
-
SCRI Development Innovations, LLCIpsenTerminatoNeoplasie gastrointestinali | Tumori neuroendocrini | Tumori carcinoidiStati Uniti
-
Chiasma, Inc.CompletatoAcromegaliaStati Uniti, Spagna, Ungheria, Francia, Regno Unito, Austria, Germania, Italia, Lituania, Polonia, Romania, Federazione Russa, Serbia
-
Eicos Sciences, Inc.CompletatoFenomeno di Raynaud secondario alla sclerosi sistemicaStati Uniti